Clinical Trial Results: Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib [Phase 2]

View source ↗

Summary

Phase II open-label single-arm trial of SAR302503 in myelofibrosis patients previously treated with ruxolitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hematopoietic Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2026-07-16